Literature DB >> 34426482

Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals.

Imraan Joosub1, Zohair Emara2, Andy Gray3.   

Abstract

BACKGROUND: Pharmacists rely heavily on available reference material to guide the extemporaneous compounding of medicines. Extemporaneous compounding for individual patients has traditionally not been closely regulated, but is necessary in every setting.
OBJECTIVE: To assess the adequacy of the evidence and recommend changes for the master formulae (MFs) used in the extemporaneous compounding manual at five Ministry of National Guard Health Affairs (MNGHA) tertiary care institutions in Saudi Arabia.
METHOD: A descriptive cross-sectional study of all extemporaneous oral liquid dosage forms (n=75) was conducted. Investigators sought to establish if the current list of compounded oral liquid dosage forms were registered commercially, backed by a stability study or followed the Saudi Arabia Food and Drug Administration guidance on assigning beyond-use dates. A literature review of stability studies, tertiary references and package inserts was used to verify the MFs. Findings of each MF were tabulated and compared with available stability studies.
RESULTS: It was found that 28 (37.3%) oral liquid dosage forms were registered by a regulatory authority, 8 (10.7%) MFs could not be traced to a stability study, while 3 (4%) MFs used beyond-use dates. The taskforce approved 15 (20%) MFs without changes, while 42 (56%) MFs had to be revised.
CONCLUSION: This review found that, although resources on the compounding of oral liquid dosage forms exist, pharmacies need to carefully assess their quality and relevance and update local policies and practices. The majority (80%) of the current MFs used in MNGHA institutions were rejected due to inappropriate compounding practices and inaccuracies. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  compounding (individualised preparation); drug formulary management; drug formulation; drug stability; good manufacturing practice (gmp); manufacturing, small scale; pharmaceutical excipients; quality assurance; shelf life; stability and incompatibility; storage conditions; validation preparation process

Mesh:

Year:  2019        PMID: 34426482      PMCID: PMC8403784          DOI: 10.1136/ejhpharm-2019-001891

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  12 in total

1.  Stability of amiodarone in an oral suspension stored under refrigeration and at room temperature.

Authors:  M C Nahata
Journal:  Ann Pharmacother       Date:  1997 Jul-Aug       Impact factor: 3.154

2.  Stability of an extemporaneously formulated levothyroxine sodium syrup compounded from commercial tablets.

Authors:  K S Alexander; M R Kothapalli; D Dollimor
Journal:  Int J Pharm Compd       Date:  1997 Jan-Feb

3.  An overview of United States pharmacopeia chapter 795 and american society of health-system pharmacists guidelines for nonsterile compounding.

Authors:  Linda F McElhiney
Journal:  Int J Pharm Compd       Date:  2009 Nov-Dec

4.  Formulation and compatibility studies are important.

Authors:  Phil Wiffen
Journal:  Eur J Hosp Pharm       Date:  2018-09-16

5.  Updating formulations for compounded oral liquid medications in a university health system.

Authors:  Janice L Stumpf; Noah Leja; Scott L Ciarkowski; Sharon Salah; Kristen L Schaeffler
Journal:  Am J Health Syst Pharm       Date:  2018-07-13       Impact factor: 2.637

6.  Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures.

Authors:  Milap C Nahata
Journal:  Int J Pharm Compd       Date:  2015 Sep-Oct

7.  Stability of an extemporaneously compounded levothyroxine sodium oral liquid.

Authors:  D W Boulton; J P Fawcett; D J Woods
Journal:  Am J Health Syst Pharm       Date:  1996-05-15       Impact factor: 2.637

8.  Formulation and accelerated stability studies for an extemporaneous suspension of amiodarone hydrochloride.

Authors:  Kenneth S Alexander; N Thyagarajapuram
Journal:  Int J Pharm Compd       Date:  2003 Sep-Oct

9.  European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism.

Authors:  Juliane Léger; Antonella Olivieri; Malcolm Donaldson; Toni Torresani; Heiko Krude; Guy van Vliet; Michel Polak; Gary Butler
Journal:  J Clin Endocrinol Metab       Date:  2014-01-21       Impact factor: 5.958

Review 10.  Potential risks of pharmacy compounding.

Authors:  Jennifer Gudeman; Michael Jozwiakowski; John Chollet; Michael Randell
Journal:  Drugs R D       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.